Cargando…
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
PAM50 intrinsic breast cancer subtypes are prognostic independent of standard clinicopathologic factors. CALGB 9741 demonstrated improved recurrence-free (RFS) and overall survival (OS) with 2-weekly dose-dense (DD) versus 3-weekly therapy. A significant interaction between intrinsic subtypes and DD...
Autores principales: | Liu, Minetta C, Pitcher, Brandelyn N, Mardis, Elaine R, Davies, Sherri R, Friedman, Paula N, Snider, Jacqueline E, Vickery, Tammi L, Reed, Jerry P, DeSchryver, Katherine, Singh, Baljit, Gradishar, William J, Perez, Edith A, Martino, Silvana, Citron, Marc L, Norton, Larry, Winer, Eric P, Hudis, Clifford A, Carey, Lisa A, Bernard, Philip S, Nielsen, Torsten O, Perou, Charles M, Ellis, Matthew J, Barry, William T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501351/ https://www.ncbi.nlm.nih.gov/pubmed/28691057 http://dx.doi.org/10.1038/npjbcancer.2015.23 |
Ejemplares similares
-
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015) -
Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019) -
Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012) -
A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)
por: Thanarajasingam, Gita, et al.
Publicado: (2016) -
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)